pubmed-article:11479223 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C0008109 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C1522449 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C0079427 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C0017638 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C0253023 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C0079419 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C0596988 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C1325410 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C0681205 | lld:lifeskim |
pubmed-article:11479223 | lifeskim:mentions | umls-concept:C1550555 | lld:lifeskim |
pubmed-article:11479223 | pubmed:issue | 15 | lld:pubmed |
pubmed-article:11479223 | pubmed:dateCreated | 2001-7-31 | lld:pubmed |
pubmed-article:11479223 | pubmed:abstractText | Adenoviral chimeric tumor suppressor 1 (CTS1) gene transfer was evaluated as a novel approach of somatic gene therapy for malignant glioma. CTS1 is an artificial p53-based gene designed to resist various pathways of p53 inactivation. Here, we report that an adenovirus encoding CTS1 (Ad-CTS1) induces growth arrest and loss of viability in all glioma cell lines examined, in the absence of specific cell cycle changes. In contrast, an adenovirus encoding wild-type p53 (Ad-p53) does not consistently induce apoptosis in the same cell lines. Electron microscopic analysis of Ad-CTS1-infected glioma cells reveals complex cytoplasmic pathology and delayed apoptotic changes. Ad-CTS1 induces prominent activation of various p53 target genes, including p21 and MDM-2, but has no relevant effects on BCL-2 family protein expression. Although Ad-CTS1 strongly enhances CD95 expression at the cell surface, endogenous CD95/CD95 ligand interactions do not mediate CTS1-induced cell death. This is because Ad-CTS1 promotes neither caspase activation nor mitochondrial cytochrome c release and because the caspase inhibitors, z-val-Ala-DL-Asp-fluoromethylketone (zVAD)-fmk or z-Ile-Glu-Thr-Asp- fluoromethylketone (z-IETD)-fmk, do not block CTS1-induced cell death. Ad-CTS1 synergizes with radiotherapy and CD95 ligand in killing glioma cells. In summary, Ad-CTS1 induces an unusual type of cell death that appears to be independent of BCL-2 family proteins, cytochrome c release, and caspases. CTS1 gene transfer is a promising strategy of somatic gene therapy for malignant glioma. | lld:pubmed |
pubmed-article:11479223 | pubmed:language | eng | lld:pubmed |
pubmed-article:11479223 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:11479223 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:11479223 | pubmed:month | Aug | lld:pubmed |
pubmed-article:11479223 | pubmed:issn | 0008-5472 | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:WellerMM | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:WolburgHH | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:KüglerSS | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:SchulzJ BJB | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:BährMM | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:NaumannUU | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:WickWW | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:ConseillerEE | lld:pubmed |
pubmed-article:11479223 | pubmed:author | pubmed-author:RascherGG | lld:pubmed |
pubmed-article:11479223 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:11479223 | pubmed:day | 1 | lld:pubmed |
pubmed-article:11479223 | pubmed:volume | 61 | lld:pubmed |
pubmed-article:11479223 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:11479223 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:11479223 | pubmed:pagination | 5833-42 | lld:pubmed |
pubmed-article:11479223 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:meshHeading | pubmed-meshheading:11479223... | lld:pubmed |
pubmed-article:11479223 | pubmed:year | 2001 | lld:pubmed |
pubmed-article:11479223 | pubmed:articleTitle | Chimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand. | lld:pubmed |
pubmed-article:11479223 | pubmed:affiliation | Laboratory of Molecular Neuro-Oncology, Department of Neurology, Institute of Pathology, University of Tübingen Medical School, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany. | lld:pubmed |
pubmed-article:11479223 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:11479223 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11479223 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11479223 | lld:pubmed |